Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 11/20 | 0.37 |
| ▸ | ESR1 | P03372 | 6/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.36 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2581201 | 0.77 | KEAP1 (0.61) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL4852032 | 0.77 | RAB9A (0.40) | CYP3A4KEAP1 | |
| SCHEMBL4849854 | 0.76 | BCL2 (0.53) | CYP3A4KEAP1 | |
| SCHEMBL4852017 | 0.76 | RAB9A (0.39) | CYP3A4KEAP1 | |
| SCHEMBL10034492 | 0.73 | CYP11B1 (0.38) | CYP3A4CYP2C9MAPTKEAP1 | |
| SCHEMBL2579031 | 0.71 | KEAP1 (0.58) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL5373105 | 0.71 | MAPT (0.50) | MAPTSLC5A1SLC5A2 | |
| SCHEMBL2574075 | 0.71 | KDM4C (0.47) | KDM4CMAPT | |
| SCHEMBL4859831 | 0.69 | LOXL2 (0.47) | CYP3A4CYP2C9MAPT | |
| SCHEMBL29410681 | 0.66 | RPS6KA3 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439232-B2 | Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-10-21 | — | — | US | disclosed |
| US-20060194809-A1 | Heteroaryl 5-thio-beta-d-gucopyranoside derivatives and therapeutic agents for diabetes containing the same | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1609799-A1 | HETEROARYL 5-THIO-BETA-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2005-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194809-A1 | Heteroaryl 5-thio-beta-d-gucopyranoside derivatives and therapeutic agents for diabetes containing the same | SLC5A2, SLC5A1, UGGT1 | KDM4C 4047/4885ESR2 2369/4885ESR1 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.